Author, Subjects, Keywords

Cited Author

 
 
   » By Author or Editor
 » Browse Author by Alphabet
 » By Journal
 » By Subjects
 » Malaysian Journals
 » By Type
 » By Year
 » By Latest Additions
 
 
   » By Author
 » Top 20 Authors
 » Top 20 Article
 » Top Journal Cited
 » Top Article Cited
 » Journal Citation Statistics
 » Usage Since Sept 2007


 
 
 

Login | Create Account

p53 : An Overview of Over Two Decades of Study

Cheah, Phaik Leng , and Looi, Lai Meng, (2001) p53 : An Overview of Over Two Decades of Study. Malaysian Journal of Pathology, 23 (1). pp. 9-16. ISSN 0126-8635

[img]
Preview
PDF - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
250Kb

Official URL: http://www.mjpath.org.my/past_issue/MJP2001.1/P53%20an%20overview%20of%20over%20two%20decades%20of%20study.pdf

Affiliations

University of Malaya, Faculty of Medicine. Dept. of Pathology
University of Malaya, Faculty of Medicine. Dept. of Pathology

Abstract

p53 is the most commonly mutated gene in human cancers. It encodes a 53 kilodalton protein with several evolutionarily conserved domains viz sequence-specific DNA binding, tetramerisation, SH3 molecule binding, C-terminal and N-terminal. Existing in the cell at a very low level and in a relatively inactive form, p53 protein is increased and activated during periods of cellular stress. Unlike other proteins, the increase in protein level and its activation result from modification of the protein rather than genetic transcriptional or translational upregulation. Normally, Mdm2 protein interacts with p53 protein and effectively targets it for ubiquitin proteolysis within an autoregulatory feedback loop. Phosphorylation at the N-terminus reduces p53 interaction with Mdm2 with a resultant increase in p53 protein level. Modification at the C and N termini via phosphorylation or acetylation upregulates binding to specific DNA targets increasing transcription of these downstream genes. The nett effect of p53 protein increase and activation lies in arrest of the cell in cycle which allows time for repair of the incurred damage or apoptosis or death of the cell. Failure of these normal protective and adaptive mechanisms caused by mutation of the p53 gene with product of an abnormal protein, loss of p53 protein through interaction with and degradation by HPV E6 protein or overexpressed Mdm2 etc. permits DNA-damaged cells to continue replicating. Left unchecked, this
frequently contributes to tumourigenesis. Various methods have been devised to screen for mutations of the p53 gene, still the most common source of failed p53 mechanism. These include immunohistochemical detection of mutated proteins or identification of altered electrophoretic mobility of
mutated p53 sequences. Sequencing of the gene nonetheless remains the most accurate method for determination of mutation. Major advances have been made in p53 research but the most meaningful probably lies in the promising results achieved in tumour therapy where introduction of wild type p53 gene has resulted in regression of non-small-cell lung cancer (NSCLC). Many other notable developments in this field include description of p53 homologues, "gain of function" mutants, p53 polymorphisms, angiogenesis-inhibiting properties of wild type p53 protein etc.

Item Type:Journal
Keywords:p53, research, mutations, screening, gene therapy, review
Subjects:R Medicine, Dentistry, Pharmacy, Nursing
ID Code:3867

1. Hemandez-Boussard T, Montesano R, Hainaut P. Sources of bias in the detection and reporting of p53 mutations in human cancer: analysis of the IARC p53 mutation database. Genet Anal 1999;14:229-33.

2. Hernandez-Boussard T, Rodriguez-Tome P, Montesano R, Hainaut P. IARC p53 mutation database: a relational database to compile and analyze p53 mutations in human tumors and cell lines. International Agency for Research on Cancer. Hum Mutat 1999; 14: 1-8.

3. Lane DP, Crawford LV. T antigen is bound to a host protein in SV40-transformed cells. Nature 1979; 278:261-3.

4. Linzer D1, Levine AJ. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma Cell 1979;17:43-52.

5. Kress M, May E, Cassingena R, May P. Simian virus 40-transformed cells express new species of proteins precipitable by anti-simian virus 40 tumor serum. J Virol 1979; 31:472-83.

6. Deleo AB, Jay G, Appella E, Dubois GC, Law LW, Old LJ. Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc Natl Acad Sci USA 1979; 76:2420-4.

7. Crawford L, Leppard K, Lane D, Harlow E. Cellular proteins reactive with monoclonal antibodies directed against simian virus 40 T-antigen. J Virol 1982; 42:612-20.

8. Jenkins JR, Rudge K, Currie A. Cellular immortalization by a cDNA clone encoding the transformation- associated phosphoprotein p53. Nature 1984; 312:651-4.

9. Parada LF, Lund H, Weinberg RA, Wolf D, Rotter V. Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation. Nature 1984; 3 12:649-5 1.

10. Eliyahu D, Raz A, Gruss P, Givol D, Oren M. Participation of p53 cellular tumour antigen in transformation of normal embryonic cells. Nature 1984; 312:646-9.

11. Zakut-Houri R, Bienz-Tadmor B, Givol D, Oren M. Human p53 cellular tumor antigen: cDNA sequence and expression in COS cells. EMBO J 1985; 4:1251-5.

12. Mowat M, Cheng A, Kimura N, Bernstein A, Benchimol S. Rearrangements of the cellular p53 gene in erythroleukaemic cells transformed by Friend virus. Nature 1985; 314:633-6.

13. Chow V, Ben David Y, Bernstein A, Benchimol S, Mowat M. Multistage Friend erythroleukemia: independent origin of tumor clones with normal or rearranged p53 cellular oncogenes. J Virol 1987;61:2777-81.

14. Rovinsky B, Munroe D, Peacock J, Mowat M, Bernstein A, Benchimol S. Deletion of 5'-coding sequences of the cellular p53 gene in mouse erythroleukemia: a novel mechanism of oncogene regulation. Mol Cell Biol 1987;7:847-53.

15. Ben David Y, Prideaux VR, Chow V, Benchimol S, Bernstein A. Inactivation of the p53 oncogene by internal deletion or retroviral integration in erythroleukemic cell lines induced by Friend leukemia virus. Oncogene 1988; 3:179-85.

16. Munroe DG, Rovinsky B, Bernstein A, Benchimol S. Loss of a highly conserved domain on p53 as a result of gene deletion during Friend virus-induced erythroleukemia. Oncogene 1988; 2:62 1-4.

17. Finlay CA, Hinds PW, Levine AJ. The p53 protooncogene can act as a suppressor of transformation. Cell 1989; 57: 1083-93.

18. Eliyahu D, Michalovitz D, Eliyahu S, Pinhasi- Kimhi 0, Oren M. Wild-type p53 can inhibit oncogene-mediated focus formation. Proc Natl Acad Sci USA 1989; 86:8763-7.

19. Prives C, Hall PA. The p53 pathway. J Pathol 1999; 187: 112-26.

20. Soussi T, May P. Structural aspects of the p53 protein in relation to gene evolution: a second look. J Molec Biol 1996; 260:623-37.

21. Arrowsmith CHP, Morrin P. New insights into p53 function from structural studies. Oncogene 1996; 12: 1379-85.

22. El-Diery WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B. Definition of a consensus binding site for p53. Nat Genet 1992; 1:45-9.

23. Bourdon JC, Deguin-Chambon V, Lelong JC et al. Further characterisation of the p53 responsive element-identification of new candidate genes for transactivation by p53. Oncogene 1997; 14:85-94.

24. Jeffrey PD, Gorina S, Pavletich NP. Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1-7 angstroms. Science 1995; 267: 1498-502.

25. Hupp TR, Meek DW, Midgley CA, Lane DP. Regulation of the specific DNA binding function of p53. Cell 1992; 71:875-86.

26. Jayaraman J, Prives C. Activation of p53 sequence specific DNA binding by short single strands of DNA requires the p53 C-terminus Cell 1995; 81:1021-9.

27. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387:296-9.

28. Kubbutat MHG, Jones SN, Voudsen KH. Regulation of p53 stability by Mdm2. Nature 1997; 387:299-303.

29. Gorina S, Pavletich NP. Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2. Science 1996; 274:lOOl-5.

30. Maki CG, Howley PM. Ubiquitination of p53 and p21 is differentially affected by ionizing and UV radiation. Mol Cell Biol 1997; 17:355-63.

31. Maltzman W, Czyzyk L. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol Cell Biol 1984;4: 1689-94.

32. Price BD, Calderwood SK. Increased sequencespecific p53-DNA binding activity after DNA damage is attenuated by phorbol esters. Oncogene 1993; 8:3055-62.

33. Fakharzadeh SS, Trusko SP, George DL. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor line. EMBO J 1991; 10: 1565-9.

34. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992; 358:80-3.

35. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 1993; 362:857-60.

36. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53- mediated transactivation. Cell 1992; 69: 1237-45.

37. Fuchs SY, Adler V, Buschmann T, Wu X, Ronai Z. Mdm2 association with p53 targets its ubiquitination. Oncogene 1998; 17:2543-7.

38. Maki CG, Huibregtse JM, Howley PM. In vivo ubiquitination and proteasome-mediated degradation of p53 1). Cancer Res 1996; 56:2649-54.

39. Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 1997; 420:25-7.

40. Midgley CA, Lane DP. p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene 1997; 15:1179-89.

41. Wu X, Bayle JH, Olson D, Levine AJ. The p53- mdm2 autoregulatory feedback loop. Genes Dev 1993; 7: 1126-32.

42. Barak Y, Juven T, Haffner R, Oren M. mdm2 expression is induced by wild type p53 activity. EMBO J 1993; 12:461-8.

43. Perry ME, Piette J, Zawadzki JA, Harvet D, Levine AJ. The mdm-2 gene is induced in response to UV light in a p53-dependent manner. Proc Natl Acad Sci USA 1993; 90:11623-7.

44. Price BD, Park SJ. DNA damage increases the levels of MDM2 messenger RNA in wtp53 human cells. Cancer Res 1994; 54:896-9.

45. Caelles C, Heimberg A, Karin M. p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature 1994; 370:220-3.

46. Gu W, Roeder RG. Activation of p53 sequencespecific DNA-binding by acetylation of the p53 C-terminal domain. Cell 1997; 90:595-606.

47. Sakaguchi K, Herrera JE, Saito S et al. DNA damage activates p53 through a phosphorylation acetylation cascade. Genes Dev 1998; 12:283 1-41.

48. Shieh S-Y, Ikeda M, Taya T, Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 1997; 91:325-34.

49. Siliciano JD, Canman CE, Taya Y, Sakaguchi K, Appella E, Kastan MB. DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev 1997; 11:3471-XI.

50. Meek D. Post-translational modification of p53. Semin Cancer Biol 1994; 5:203-7.

51. Ashcroft M, Voudsen KH. Regulation of p53 stability.

Oncogene 1999; 18:7637-43.

52. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4A locus tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995; 83:993-1000.

53. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilises p53: ARFINK4a locus deletion impairs both the Rb and p53 tumor suppressor pathways. Cell 1998; 92:725-34.

54. Stott F, Bates SA, James M et al. The alternative product from the human CDKN2A locus, pl4ARF. participates in a regulatory feedback loop with p53 and MDM2. EMBO J 1998; 17:5001-4.

55. Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF, Sherr CJ. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci USA 1998; 95:8292-7.

56. Pomerantz J, Schreiber-.Zgus N, Liegeois NJ, et al. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998; 92:713-23.

57. Wang Y, Prives C. Increased and altered DNA binding of human p53 by S and G2/M but not G1 cyclin-dependent kinases. Nature 1995; 376:88-91.

58. Hupp TR, Lane DP. Allosteric activation of latent

p53 tetramers. Curr Biol 1994; 4:865-75.

59. Takenaka I, Morin F, Seizinger BR, Kley N. Regulation

of the sequence-specific DNA binding function of p53 by protein kinase C and protein phosphatases. J Biol Chem 1995; 270:5405-I 1.

60. Avantaggiati ML, Ogryzko K, Gardner K, Giordano A, Levine AS, Kelly K. Recruitment of p3001CBP in p53-dependent signal pathways. Cell 1997;89: 1 175-84.

61. Gu W, Shi X-L, Roeder RG. Synergistic activation of transcription by CBP and p53. Nature 1997; 387:819-23.

62. Gu W, Roeder RG. Activation of p53 sequencespecific

DNA binding by acetylation of the p53 Cterminal domain. Cell 1997; 91 :595-606.

63. MacCallum DE, Hupp TR, Midgley CA et al. The p53 response to ionising radiation in adult and developing murine tissues. Oncogene 1996: 13:2575-87.

64. Midgley CA, Owens B, Briscoe CV, Thomas DB, Lane DP, Hall PA. Coupling between gamma irradiation, p53 induction and the apoptotic response depends on cell type in vivo. Cell Sci 1995; 108:1841-43.

65. Johnson DG, Schwarz JK, Cress WD, Nevins JR. Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature 1993: 365:349-52.

66. Chellappan SP, Hiebert S, Mudryj M, Horowitz JM, Nevins JR. The E2F transcription factor is a cellular target for the RB protein. Cell 1991; 65:1053-61.

67. El-Diery WS, Tokino T, Velculescu VE et al. WAFI, a potential mediator of p53 tumor suppression. Cell 1993; 75:817-25.

68. 0' Connor PM. Mammalian G1 and G2 phase checkpoints. Cancer Surv 1997; 29: 15 1-82.

69. Elledge SJ. Cell cycle checkpoints: preventing an

identity crisis. Science 1996; 274: 1664-72.

70. Zhan Q, Antinore MJ, Wang XW et al. Association with Cdc2 and inhibition of Cdc2/Cyclin B 1 kinase activity by the p53-regulated protein Gadd45. Oncogene 1999; 18:2892-900

71. Stewart N, Hicks GG, Paraskevas F, Mowat M. Evidence for a second cell cycle block at G2/M by p53. Oncogene 1995; 10: 109-15.

72. Maity A, McKenna WC, Muschel RJ. Evidence for post-transcriptional regulation of cyclin B1 mRNA in the cell cycle and following irradiation in HeLa cells. EMBO J 1995; 14:603-9.

73. Agarwal ML, Agarwal A, Taylor WR, Stark GR. p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc Natl Acad Sci USA 1995; 92:8493-7.

74. Medema RH, Klompmaker R. Smits VA, Rijksen G. p21 waf I can block cells at two points in the cell cycle, but does not interfere with processive DNAreplication or stress-activated kinases. Oncogene 1998; 16:431-41.

75. Zhan Q, Fan S, Bae I et al. Induction of bax by

genotoxic stress in human cells correlates with normal p53 status and apoptosis. Oncogene 1994: 93743.5 1.

76. Miyashita T, Krajewski S. Krajewska M et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994; 9: 1799-805.

77. Owen-Schaub LB. Zhang W. Cusack JC et al. Wild-type human p53 and a temperature-sensitive mutant induce FasIAPO-1 expression. Mol Cell Biol 1995; 15:3032-40.

78. Isreali D, Tessler E, Haupt Y et al. A novel p53-

inducible gene, PAG608, encodes a nuclear zinc finger protein whose overexpression promotes apoptosis. EMBO J 1997; 16:4384-92.

79. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54:4855-78.

80. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990; 248:76-9.

81. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus 16 and 18 promotes the degradation of p53. Cell 1990; 63:1129-36.

82. Moll U, Riou G, Levine AJ. Two distinct mechanisms

alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci USA 1992;89:7262-6.

83. Moll U, Laquaglia M, Benard J, Riou G. Wildtype p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc Natl Acad Sci USA 1995; 92:4407-11.

84. Moll U, Ostermeyer AG, Haladay R, Winkfield B, Frazier M, Zambetti G. Cytoplasmic sequestration of wild-type p53 protein impairs the G1 checkpoint after DNA damage. Mol Cell Biol 1996; 16: 1126-37.

85. Malkin D, Li FP, Strong LC et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas and other neoplasms. Science 1990; 250:1233-8.

86. Ullrich SJ, Anderson CW, Mercer WE, Appella E. The p53 tumor suppressor protein, a modulator of cell proliferation. J Biol Chem 1992; 267: 15259-62.

87. Davidoff AM, Hemdon JE, Glover NS, Kerns BJ, Iglehart JD, Marks JR. Relation between p53 overexpression and established prognostic factors in breast cancer. Surgery 1991; 110:259-64.

88. Wolff JM, Habib FK. Tumor suppressor genes in urologic tumors. Urology 1993; 42:461-6.

89. Finlay CA, Hinds PW, Tan TH, Elliyahu D, Oren M, Levine AJ. Activating mutations for transformation by p53 produce a gene product that forms an hsc-70.~53 complex with an altered half life. Mol Cell Biol 1988; 8:531.

90. Smith-Sorensen B, Gebhardt MC, Kloen P et al. Screening for TP53 mutations in osteosarcomas using constant denaturant gel electrophoresis (CDGE). Hum Mutat 1993; 2:274-85.

91. Orita M, Iwahana H, Kanazawa H, Hayashi K, Sekiya T. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc Natl Acad Sci USA 1989; 86:2766-70.

92. Murukami Y, Hayashi K, Sekiya T. Detection of

aberrations of the p53 alleles and the gene transcript in human tumor cell lines by single-strand conformation polymorphisms analysis. Cancer Res 1991; 51:3356-61.

93. Borresen AL, Hovig E, Smith-Sorensen B et al. Constant denaturant gel electrophoresis as a rapid screening technique for p53 mutations. Proc Natl Acad Sci USA 1991; 8823405-9.

94. Roth JA, Nguyen D. Lawrence DD et al. Retrovimsmediated

wild-type p53 gene transfer to tumors of patients with lung cancer. Nature Med 1996; 2:985-90.

95. Foster BA, Coffey HA, Morin MJ, Rastinejad F.

Pharmacological rescue of mutant p53 conformation and function. Science 1999; 286:2507-10.

96. Gualberto A, Aldape K, Kozakiewicz K, Tisty TD. An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control. Proc Natl Acad Sci USA 1998; 95:5166-71.

97. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin- l. Science 1994;265: 1582-4.

98. Storey A, Thomas M, Kalita A et al. Role of a p53

polymorphism in the development of human papillomavirus-associated cancer. Nature 1998;393:229-34.

99. Wang-Gohrke S, Rebbeck TR, Besenfelder W, Kreienberg R, Runnebaum IB. p53 germline polymorphisms are associated with an increased risk for breast cancer in German women. Anticancer Res 1998; 18:2095-9.

100. Buller RE, Sood A, Fullenkamp C, Sorosky J, Powills K, Anderson B. The influence of p53 codon 72 polymorphism on ovarian carcinogenesis and prognosis. Cancer Gene Ther 1997;

4:239-45.

101. Knudson AGJ. Hereditary cancer, oncogenes, and

antioncogenes. Cancer Res 1985; 45:1437-43.

102. Venkatachalam S, Shi Y-P, Jones SN et al. Retention

of wild-type p53 tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO J 1998;17:4657-67.

103. Kaghad M, Bonnet H, Yang A et al. Monoallelically

expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997; 90:809-19.

104. Schmale S, Bamberger C. A novel protein with strong homology to the tumour suppressor p53. Oncogene 1997; 15: 1363-7.

Repository Staff Only: item control page
 
 
 
 
 
 
© Copyright 2007 MyAIS Faculty of Computer Science and Information Technology, University of Malaya – All Rights Reserved. Malaysian Abstracting and Indexing System is powered by EPrints 3 which is developed by the School of Electronics and Computer Science at the University of Southampton. More information and software credits.